An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer.

Mar 15, 2021

Contributor: Zhijun Zhou,Junxia Zhang,Chao Xu,Jingxuan Yang,Yuqing Zhang,Mingyang Liu,Xiuhui Shi,Xiaoping Li,Hanxiang Zhan,Wei Chen,Lacey R McNally,Kar-Ming Fung,Wenyi Luo,Courtney W Houchen,Yulong He,Changhua Zhang,Min Li

An integrated model of N6-methyladenosine regulators to predict tumor aggressiveness and immune evasion in pancreatic cancer.

N6-methyladenosine (m6A) is the most abundant mRNA modification. Whether m6A regulators can determine tumor aggressiveness and risk of immune evasion in pancreatic ductal adenocarcinoma (PDAC) remains unknown.
An integrated model named “m6Ascore” is constructed based on RNA-seq data of m6A regulators in PDAC. Association of m6Ascore and overall survival is validated across several different datasets. Overlaps of m6Ascore and established molecular classifications of PDAC is examined. Immune infiltration, enriched pathways, somatic copy number alterations (SCNAs), mutation profiles and response to immune checkpoint inhibitors are compared between m6Ascore-high and m6Ascore-low tumors.
m6Ascore is associated with dismal overall survival and increased tumor recurrence in PDAC as well as several other solid tumors including colorectal cancer and breast cancer. Basal-like (Squamous) PDAC has higher m6Ascore than that in the classical PDAC. Mechanism study showed m6Ascore-high tumors are characterized with reduced immune infiltration and T cells exhaustion. Meanwhile, m6Ascore is associated with genes regulating cachexia and chemoresistance in PDAC. Furthermore, distinct SCNAs patterns and mutation profiles of KRAS and TP53 are present in m6Ascore-high tumors, indicating immune evasion. m6Ascore-low tumors have higher response rates to immune checkpoint inhibitors (ICIs).
These findings indicate m6Ascore can predict aggressiveness and immune evasion in pancreatic cancer. This model has implications for pancreatic cancer prognosis and treatment response to ICIs.
This work was supported in part by National Institutes of Health (NIH) grants to M. Li (R01 CA186338, R01 CA203108, R01 CA247234 and the William and Ella Owens Medical Research Foundation) and NIH/National Cancer Institute Q39 award P30CA225520 to Stephenson Cancer Center.

Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.

Author

admin

View all posts

About The Expert

Zhijun Zhou

Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.

Junxia Zhang

Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.

Chao Xu

Department of Biostatistics and Epidemiology, Hudson College of Public Health, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.

Jingxuan Yang

Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.

Yuqing Zhang

Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.

Mingyang Liu

Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.

Xiuhui Shi

Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.

Xiaoping Li

Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.

Hanxiang Zhan

Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.

Wei Chen

Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-sen University, 628 Zhenyuan Road, Shenzhen, Guangdong 518107, China.

Lacey R McNally

Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.

Kar-Ming Fung

Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.

Wenyi Luo

Department of Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.

Courtney W Houchen

Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.

Yulong He

Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-sen University, 628 Zhenyuan Road, Shenzhen, Guangdong 518107, China.

Changhua Zhang

Digestive Diseases Center, The Seventh Affiliated Hospital of Sun Yat-sen University, 628 Zhenyuan Road, Shenzhen, Guangdong 518107, China. Electronic address: zhchangh@mail.sysu.edu.cn.

Min Li

Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States; Department of Surgery, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States. Electronic address: Min-Li@ouhsc.edu.

References

PubMed